https://star-therapeutics.com/star-therapeutics-emerges-from-stealth-mode-raising-100m-in-financing-since-inception-to-be-an-innovation-engine-for-rare-disease-therapies/2024-06-25T14:25:02-05:00https://star-therapeutics.com/vega-therapeutics-launches-and-unveils-its-first-in-class-antibody-therapy-for-von-willebrand-disease-at-ash-annual-meeting/2023-05-05T08:49:19-05:00https://star-therapeutics.com/vega-therapeutics-initiates-clinical-trial-program-for-vga039-a-first-in-class-antibody-therapy-for-von-willebrand-disease/2023-05-05T08:50:48-05:00https://star-therapeutics.com/vega-therapeutics-receives-fda-orphan-drug-designation-for-vga039-for-the-treatment-of-von-willebrand-disease/2023-05-22T21:49:30-05:00https://star-therapeutics.com/star-therapeutics-raises-90-million-financing-to-accelerate-its-pipeline-of-novel-antibody-therapies-and-growth-of-its-portfolio-companies/2023-09-04T21:05:36-05:00https://star-therapeutics.com/star-therapeutics-appoints-matthew-fust-as-independent-director-and-audit-chair/2023-12-05T08:51:39-06:00https://star-therapeutics.com/star-therapeutics-appoints-scott-robertson-chief-business-officer-cfo/2024-01-01T16:33:51-06:00https://star-therapeutics.com/star-therapeutics-to-present-at-42nd-annual-jp-morgan-healthcare-conference/2024-01-01T16:34:44-06:00https://star-therapeutics.com/star-therapeutics-presents-clinical-data-for-vga039-a-subcutaneous-therapy-for-the-treatment-of-von-willebrand-disease-vwd/2024-06-26T10:43:52-05:00https://star-therapeutics.com/wp-content/uploads/2026/04/VGA039-Phase1-2-Presentation-ASH-12-6-2025.pdf#new_tab2026-04-20T14:33:43-05:00https://star-therapeutics.com/star-therapeutics-presents-interim-clinical-data-for-vga039-in-patients-with-von-willebrand-disease-vwd-at-ash-2024/2025-01-02T07:50:27-06:00https://star-therapeutics.com/star-therapeutics-to-present-at-43rd-annual-jp-morgan-healthcare-conference/2025-01-06T08:08:57-06:00https://star-therapeutics.com/star-therapeutics-receives-fda-fast-track-designation-for-vga039-in-von-willebrand-disease-vwd/2025-01-06T08:01:29-06:00https://www.labiotech.eu/trends-news/von-willebrand-disease-treatment-advancements/#new_tab2025-01-10T17:12:55-06:00https://star-therapeutics.com/star-therapeutics-announces-oversubscribed-125-million-series-d-financing/2025-10-06T17:01:47-05:00https://endpoints.news/star-gets-125m-series-d-as-it-begins-phase-3-in-bleeding-disorders/#new_tab2025-10-07T14:08:05-05:00https://www.fiercebiotech.com/biotech/star-therapeutics-collects-shiny-125m-funding-boost-push-bleeding-disorder-prospect-orbit#new_tab2025-10-07T14:06:51-05:00https://www.biopharmadive.com/news/star-therapeutics-von-willebrand-series-d/761286/#new_tab2025-10-07T14:07:16-05:00https://star-therapeutics.com/star-therapeutics-to-present-interim-data-from-phase-1-2-multidose-study-of-vga039-in-von-willebrand-disease-at-ash-annual-meeting/2025-11-02T14:31:10-06:00https://star-therapeutics.com/star-therapeutics-presents-interim-data-from-phase-12-multidose-study-of-vga039-in-von-willebrand-disease-demonstrating-substantial-bleed-reductions-in-all-patients-at-ash-annual-meeting/2025-12-05T16:12:14-06:00https://www.biotechtv.com/post/star-therapeutics-ash-2025#new_tab2025-12-22T14:54:49-06:00https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success#new_tab2025-12-23T14:40:47-06:00https://endpoints.news/ash25-star-therapeutics-details-early-data-for-blood-disorder-shot-weighs-ipo/#new_tab2025-12-22T15:32:23-06:00https://star-therapeutics.com/star-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-monday-january-12/2026-01-04T09:57:56-06:00https://star-therapeutics.com/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease-prophylaxis/2026-04-20T17:27:44-05:00